A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
Latest Information Update: 16 Dec 2025
At a glance
- Drugs BioTTT 001 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Beijing Bio-Targeting Therapeutics Technology
Most Recent Events
- 02 Dec 2025 Status changed from recruiting to withdrawn prior to enrolment because the applicant voluntarily withdrew the case.
- 09 Sep 2025 New trial record